ライフサイエンスコーパス: rotavirus gastroenteritis

1 hip between IgA thresholds and occurrence of rotavirus gastroenteritis.

2 Serum Institute of India) to prevent severe rotavirus gastroenteritis.

3 al stools, and 344 (19.8%) children ever had rotavirus gastroenteritis.

4 ssociation of secretor status against severe rotavirus gastroenteritis.

5 cted (98% [95% CI, 84%-100%]) against severe rotavirus gastroenteritis.

6 and broadly heterologous protection against rotavirus gastroenteritis.

7 level immune correlate of protection against rotavirus gastroenteritis.

8 ody titers correlate with protection against rotavirus gastroenteritis.

9 de the broadest degree of protection against rotavirus gastroenteritis.

10 shedding burden among breakthrough cases of rotavirus gastroenteritis.

11 specimens of Bangladeshi children with acute rotavirus gastroenteritis.

12 accine program will avert 1 026 000 cases of rotavirus gastroenteritis, 78 000 inpatient admissions,

13 bservation, vaccine efficacy was 76% against rotavirus gastroenteritis, 83% against severe rotavirus

14 n of only G2 strains in these 3 outbreaks of rotavirus gastroenteritis among adults is similar to res

15 s led to declines in hospital admissions for rotavirus gastroenteritis among children; however, the g

16 ine, had an efficacy of 66.7% against severe rotavirus gastroenteritis among infants in Niger.

17 ldren may translate to an enhanced burden of rotavirus gastroenteritis among this group.

18 % uncertainty interval [UI] 51-103) cases of rotavirus gastroenteritis and 21 million (12-36) clinic

19 erse events and is efficacious in preventing rotavirus gastroenteritis and associated healthcare enco

20 otavirus gastroenteritis, 83% against severe rotavirus gastroenteritis, and 100% against rotavirus il

21 ompetent children who required treatment for rotavirus gastroenteritis at a large pediatric hospital

22 sk ratios (number of hospitalisations due to rotavirus gastroenteritis averted per excess hospitalisa

23 Rotavirus gastroenteritis case data were extracted from

24 nce of RV1-derived NSP2 sequences in 7.7% of rotavirus gastroenteritis cases and 98.6% of rotavirus-p

25 e studies have shown substantial declines in rotavirus gastroenteritis cases and deaths globally, the

26 8.4 months, coinciding with a peak in severe rotavirus gastroenteritis cases at 9 months.

27 ated age structure to estimate the number of rotavirus gastroenteritis cases, clinic visits, hospital

28 inistic cohort model to calculate numbers of rotavirus gastroenteritis cases, outpatient visits, hosp

29 he field effectiveness of RV1 against severe rotavirus gastroenteritis caused by this unusual strain

30 pidemiologic association among children with rotavirus gastroenteritis compared with healthy control

31 00 (95% uncertainty interval 59 000-100 000) rotavirus gastroenteritis deaths (38% reduction) and cou

32 schedules have the potential to prevent more rotavirus gastroenteritis deaths and cause fewer excess

33 Numbers of rotavirus gastroenteritis deaths and intussusception dea

34 Benefit-risk ratios (rotavirus gastroenteritis deaths prevented per excess in

35 needed to be immunised to prevent one severe rotavirus gastroenteritis episode was 55 (95% CI 37-97).

36 median age and the cumulative proportion of rotavirus gastroenteritis events expected to occur at ag

37 we recruited infants presenting with severe rotavirus gastroenteritis following monovalent oral rota

38 nd approximatel 100% efficacy against severe rotavirus gastroenteritis for the first rotavirus infect

39 As IgA threshold increased, risk of rotavirus gastroenteritis generally decreased.

40 The primary outcome was incidence of severe rotavirus gastroenteritis (>/=11 on the Vesikari scale).

41 Children recovering from rotavirus gastroenteritis have increased gamma interfero

42 vaccine and the impact of Rotarix vaccine on rotavirus gastroenteritis hospitalisations (ie, hospital

43 showed moderate effectiveness in preventing rotavirus gastroenteritis hospitalisations, consistent w

44 1 (Rotarix) rotavirus vaccines in preventing rotavirus gastroenteritis hospitalizations and emergency

45 ore doses of rotavirus vaccine in preventing rotavirus gastroenteritis hospitalizations ranged from 8

46 vided near perfect protection against severe rotavirus gastroenteritis (HR, 0.04; 95% confidence inte

47 sion dramatically reduced the risk of severe rotavirus gastroenteritis (HR, 0.46; 95% CI, .25-.86).

48 ns, and 37 900 (25 900-55 900) deaths due to rotavirus gastroenteritis in 63 MICs not eligible for Ga

49 real-time PCR to establish the diagnosis of rotavirus gastroenteritis in a high-disease-burden popul

50 as evaluated by comparing the frequencies of rotavirus gastroenteritis in an intention-to-treat analy

51 The prominent decline in severe rotavirus gastroenteritis in areas with mature rotavirus

52 s vaccines have reduced the health burden of rotavirus gastroenteritis in both developed and developi

53 the best hope of reducing the toll of acute rotavirus gastroenteritis in both developed and developi

54 Outbreaks of rotavirus gastroenteritis in elderly adults are reported

55 strongly associated with protection against rotavirus gastroenteritis in high-income countries, weak

56 cted toward development of a vaccine against rotavirus gastroenteritis in infants.

57 nt human-bovine rotavirus vaccine for severe rotavirus gastroenteritis in low-resource urban and rura

58 infection on the presentation and outcome of rotavirus gastroenteritis in Malawian children.

59 vaccine introduction on admissions for acute rotavirus gastroenteritis in primarily low-income and mi

60 ssess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduct

61 cacy analysis, there were 31 cases of severe rotavirus gastroenteritis in the vaccine group and 87 ca

62 icantly protected against medically attended rotavirus gastroenteritis in this real-world assessment.

63 negative design, rotavirus VE against severe rotavirus gastroenteritis increased from 49.3% to 60.6%

64 However, the incidence of rotavirus gastroenteritis is predicted to remain low des

65 Each year, rotavirus gastroenteritis is responsible for about 37% o

66 tified with clinical or laboratory-confirmed rotavirus gastroenteritis (median age, 84 years) and 11

67 cantly lower rates of hospitalization with a rotavirus gastroenteritis or unspecified-gastroenteritis

68 The incidence of severe rotavirus gastroenteritis per 100 person-years was 1.5 i

69 Rotavirus gastroenteritis rates among rotavirus vaccines

70 emonstrated 68.8%-76.6% efficacy against any rotavirus gastroenteritis, regardless of severity, and a

71 ce interval [CI], 31%-91%) effective against rotavirus gastroenteritis requiring hospitalization or a

72 en maternal antibody titer is low and severe rotavirus gastroenteritis risk is high, may enhance the

73 programs effectively protect against severe rotavirus gastroenteritis, rotavirus vaccine strains hav

74 study examined RRV-TV for the prevention of rotavirus gastroenteritis (RV-GE) in Ghana, West Africa,

75 tural and vaccine-derived protection against rotavirus gastroenteritis (RVGE) in low- and middle-inco

76 ny-severity and severe (Vesikari score >=11) rotavirus gastroenteritis (RVGE) using binomial and mult

77 estimated VE against any-severity and severe rotavirus gastroenteritis (RVGE) using Poisson regressio

78 estimated VE against any-severity and severe rotavirus gastroenteritis (RVGE) using Poisson regressio

79 ength of naturally acquired immunity against rotavirus gastroenteritis (RVGE), mirroring vaccine unde

80 predict genotype-specific susceptibility to rotavirus gastroenteritis (RVGE).

81 The age distribution of children with rotavirus gastroenteritis shifted towards older children

82 titute of India, Pune, India) against severe rotavirus gastroenteritis (SRVGE) among healthy infants

83 rts of children with acute or fatal cases of rotavirus gastroenteritis testing positive for rotavirus

84 Two new vaccines against severe rotavirus gastroenteritis that have high efficacy in mid

85 ochester, NY, with sequence-confirmed G8P[4] rotavirus gastroenteritis-the first U.S. detection of th

86 the morbidity and mortality associated with rotavirus gastroenteritis through vaccination is support

87 ubstantial protection against any and severe rotavirus gastroenteritis to age 1 year.

88 s a valuable correlate of protection against rotavirus gastroenteritis to age 1 year.

89 llected from 196 children who presented with rotavirus gastroenteritis to health facilities in Blanty

90 first episode of laboratory-confirmed severe rotavirus gastroenteritis (Vesikari score, >/=11) beginn

91 acebo group; vaccine efficacy against severe rotavirus gastroenteritis was 53.6% (95% CI 35.0-66.9; p

92 cine effectiveness of 3 doses against severe rotavirus gastroenteritis was 54% (95% confidence interv

93 The median age of children with rotavirus gastroenteritis was 7.8 months, compared with

94 Surveillance for rotavirus gastroenteritis was conducted in 2 hospitals i

95 Severe rotavirus gastroenteritis was virtually absent among US

96 71 events of severe rotavirus gastroenteritis were reported in 4752 person-y

97 io of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negati

98 A correlate of protection for rotavirus gastroenteritis would facilitate rapid assessm